Capricor Therapeutics (FRA:4LN2) Current Accrued Expense : €5.75 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Capricor Therapeutics Current Accrued Expense?

Capricor Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2024 was €5.75 Mil.

Capricor Therapeutics's quarterly Current Accrued Expense declined from Sep. 2023 (€6.36 Mil) to Dec. 2023 (€0.00 Mil) but then increased from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€5.75 Mil).

Capricor Therapeutics's annual Current Accrued Expense declined from Dec. 2021 (€3.29 Mil) to Dec. 2022 (€0.00 Mil) but then stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Capricor Therapeutics Current Accrued Expense Historical Data

The historical data trend for Capricor Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics Current Accrued Expense Chart

Capricor Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

0.81

2.24

3.29

Capricor Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															5.07	4.74	6.36	-	5.75

Capricor Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Capricor Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Capricor Therapeutics (FRA:4LN2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (FRA:4LN2) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

CAPR:USA

Address

10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121

Website

https://www.capricor.com

Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.

Capricor Therapeutics (FRA:4LN2) Headlines

No Headlines